WP5 ensures the implementation of HARMONY PLUS results by optimizing the flow and exchange of knowledge, information, and guidance to various target audiences. Internal communication activities will promote co-operation and engagement of the Partners. External communication activities will ensure the dissemination of progress and results to relevant stakeholder groups. This will maximize the project’s impact on accelerating the development of new drugs and therapies for HM patients. The communication activities are built on and benefit from the fundamentals established by the initial HARMONY project [LINK].
EHA (Lead), IECSCYL, Hospital La Fe, GMV, UNIBO, LeukaNET, Synapse, NICE, Novartis, Pfizer.
Learn more about the HARMONY PLUS communication strategy >
Read the HARMONY Alliance - HARMONY & HARMONY PLUS - Manifesto > (2023)
Check out the HARMONY Alliance - Become involved flyer > (2023)
Read the lastest edition of the HARMONY Alliance brochure > (March 2024)
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
